Biosig Technologies (NASDAQ:STEX) Director Buys $17,160.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Director Morgan Lee Lekstrom acquired 5,500 shares of the business's stock in a transaction dated Tuesday, January 27th. The stock was purchased at an average price of $3.12 per share, with a total value of $17,160.00. Following the acquisition, the director owned 76,500 shares of the company's stock, valued at approximately $238,680. This trade represents a 7.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.Morgan Lee Lekstrom also recently made the following trade(s): On Monday, January 26th, Morgan Lee Lekstrom bought 23,000 shares of Biosig Technologies stock. The shares were purchased at an average cost of $3.30 per share, for a total transaction of $75,900.00. On Friday, January 23rd, Morgan Lee Lekstrom purchased 41,000 shares of Biosig Technologies stock. The stock was acquired at an average cost of $3.13 per share, with a total value of $128,330.00. Get Biosig Technologies alerts:Biosig Technologies Trading Up 3.8%Shares of NASDAQ:STEX traded up $0.13 during trading hours on Tuesday, hitting $3.53. 2,191,465 shares of the company's stock traded hands, compared to its average volume of 1,288,933. The firm has a market cap of $524.59 million, a price-to-earnings ratio of -2.61 and a beta of 1.48. Biosig Technologies, Inc. has a 52 week low of $0.40 and a 52 week high of $14.11. Biosig Technologies News SummaryHere are the key news stories impacting Biosig Technologies this week: Positive Sentiment: Company insiders have been buying material amounts of stock, signaling insider confidence: Director Morgan Lee Lekstrom purchased a series of lots (41,000 on Jan. 23; 23,000 on Jan. 26; and 5,500 on Jan. 27) at roughly $3.12–$3.30, bringing his ownership to 76,500 shares. Lekstrom Jan 23 SEC Filing Lekstrom Jan 26 SEC Filing Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares (~$3.03 avg), increasing his stake to over 1 million shares — another significant insider buy that investors often view as a bullish signal. Williams SEC Filing Neutral Sentiment: A separate press release for "Streamex Corp. NASDAQ: STEX" announced the closing of a $35M public offering. That release appears tied to the same ticker symbol and could be creating ticker-driven volume/noise for STEX trades; relevance to Biosig’s fundamentals is unclear. Streamex $35M Offering Negative Sentiment: Recent analyst coverage is mixed-to-negative: Weiss Ratings began coverage with a "sell (D-)" assessment, and MarketBeat shows an average analyst view of "Sell" — this could cap upside if broader investor sentiment follows analysts. Weiss Ratings Analyst Upgrades and DowngradesSeparately, Weiss Ratings assumed coverage on Biosig Technologies in a research note on Friday. They set a "sell (d-)" rating for the company. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of "Sell".Read Our Latest Stock Analysis on STEXBiosig Technologies Company Profile (Get Free Report)Biosig Technologies NASDAQ: STEX is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions. Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.See AlsoFive stocks we like better than Biosig TechnologiesHow a Family Trust May Be Able To Help Preserve Your WealthDo not delete, read immediatelyRefund From 1933: Trump’s Reset May Create Instant WealthNEW LAW: Congress Approves Setup For Digital Dollar?The $100 Trillion AI Story No One Is Telling YouThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Biosig Technologies Right Now?Before you consider Biosig Technologies, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biosig Technologies wasn't on the list.While Biosig Technologies currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here